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Abstract
Background: Neuron navigator 2 (NAV2) encodes a member of the neuron navigator gene family, which plays a
role in tumorigenesis and cell migration. However, the prognostic value of NAV2 expression in colorectal cancer
(CRC) patients and the potential pathway through which NAV2 promotes migration and invasion in CRC cell lines is
poorly understood.
Methods: The expression level of NAV2 was detected in CRC tissues from two different CRC cohorts by
immunohistochemistry, qRT-PCR and Western blotting; the correlation between NAV2 expression and clinicopathological
characters was analyzed, and the prognostic value of NAV2 expression was analyzed using a Cox regression model. CRC
cell lines with NAV2 knocked out were used to validate the function and potential pathway used by NAV2 to promote
CRC cell migration and invasion.
Results: The results showed that NAV2 was overexpressed in CRC tissues, and it was closely correlated with depth of
invasion, and lymph and distant metastasis. Multivariate analysis indicated that high NAV2 expression was a poor
prognostic indicator of recurrence-free survival and overall survival in CRC patients. Furthermore, Cox regression
analysis revealed that high NAV2 expression integrated with high tumor budding grade was a powerful independent
predictive factor of CRC clinical outcome. In vitro and in vivo assays demonstrated that knockdown of NAV2 led to
reduced migration and invasion of cancer cells, and the process involved the regulation of F-actin polymerization
through the SSH1L/cofilin-1 pathway.
Conclusion: Based on these findings, NAV2 could serve as both a prognostic biomarker and a potential therapeutic
target for patients with NAV2-positive CRC.
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Background
Colorectal cancer (CRC) is a leading cause of cancer
mortality worldwide [1]. Many improvements have
been made in screening, detection and adjuvant therapy
for CRC in recent years [2, 3]. However, the long-term
survival associated with this malignant disease is not
satisfactory due to tumor recurrence and metastasis [4].
To improve the prognosis of CRC patients, there is a
great need to identify efficient new targets for effective
disease management.
Neuron navigator 2 (NAV2) is one of three members
of the neuron navigator family [5]. NAV2 protein con-
tains various functional domains, including a calponin
homology (CH) domain, four coiled-coil (CC) domains,
a cytoskeletal interacting domain (CSID), and an AAA-
domain [6]. The functional domains were shown to be
involved in a variety of cellular processes, including pro-
tein degradation, signal transduction, regulation of gene
expression, membrane fusion, microtubule dynamics
and cell migration. It has been proven that NAV2 affects
cell migration via adjusting microtubule dynamics [7, 8],
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and microtubule dynamics induces basement membrane
breakdown, actin stress fiber formation, metal matrix
protease secretion [9]. NAV2 also regulates the cytoskel-
eton, which affects cell-cell and cell-matrix adhesion, fa-
cilitating tumor cell invasion and metastasis [10].
The actin cytoskeleton plays a central role in cell mi-
gration by mediating processes such as cell-substrate
adhesion, protrusion, phagocytosis and cytokinesis [11].
Cofilin is an essential regulator of actin dynamics, and
researchers have revealed that phosphorylation and in-
activation of cofilin-1 was capable of blocking actin
polymerization and metastasis in cancers [12, 13]. Cofilin
is inactivated by phosphorylation at Ser-3 by LIM kinase
and reactivated by dephosphorylation by the cofilin-
phosphatase, Slingshot (SSH) [13, 14]. Meanwhile, the
NAV2 homolog, Sickie, regulates actin dynamics via the
(SSH)-cofilin pathway [15]. NAV2 was deemed to be one
of target genes of APC/Wnt/β-catenin, which is a signal-
ing pathway that plays an essential role in tumor progres-
sion according to studies using the CRC cell line SW480
[16]. Moreover, NAV2 was reported to be highly expressed
in neuroblastoma cells and uterine endometrial stromal
sarcoma [17, 18], as well as in a small group of CRC pa-
tients [16].
In sum, we can infer that NAV2 is overexpressed in
CRC, and it promotes invasion and metastasis via its im-
pact on actin or microtubule dynamics and its involve-
ment in the SSH1L/cofilin-1 pathway. The objectives of
this study were to investigate the mRNA and protein ex-
pression levels of NAV2 in CRC, the role of NAV2 in
CRC cell migration and invasion, the prognostic value of
NAV2 expression in CRC patients, and the potential
pathways by which NAV2 exerts its influence on actin
dynamics.
Materials and methods
Clinical specimens and follow-up
Tumor and paired normal mucosa tissues were re-
moved by surgery from 138 CRC patients (cohort 1)
at the XiangYa Hospital (Changsha, China) between
January 2007 and December 2008. The samples were
then embedded in paraffin. Follow-up of patients in
cohort 1 was terminated on March 30, 2015. Recurrence-
free survival (RFS) was defined as time to any event, irre-
spective of cause, except for any second primary cancers.
Recurrence of or death from the same cancer and all
treatment-related deaths or deaths from other causes are
events. Second primary same cancers and other primary
cancers are ignored, and loss to follow-up is censored.
Overall survival (OS) was defined as time to death, irre-
spective of cause. Local recurrence, distant metastases,
second primary colorectal cancers, and second other pri-
mary cancers are ignored. Loss to follow-up is censored
[19]. Fresh cancerous colorectal and paired normal
mucosa tissues from 76 patients (cohort 2) were pro-
cured from the Department of General Surgery of
XiangYa Hospital of Central South University between
December 2013 and August 2014. Paired tissues were
tested by real-time qRT-PCR, and 16 paired tissues
were selected randomly for Western blotting analysis.
Primary tumor and paired metastatic tumor tissues
(lymph node, peritoneal metastasis or liver metastasis)
from 16 patients were selected for Western blotting
analysis. All procedures were in compliance with the
ethical guidelines of the XiangYa Hospital. The normal
mucosa was excised 5 cm away from the tumor and was
confirmed by pathologists for absence of tumor cells.
Tumor stage was classified according to the 7th edition of
the AJCC TNM staging system for CRC.
Estimation of tumor budding and immunohistochemical
staining
Hematoxylin-eosin (H & E) staining was performed on
138 CRC samples. The degree of tumor budding was
classified as low-grade or high-grade, corresponding to
0–9 and ≥10 in one 20× field, respectively [20]. The
protocol for immunohistochemical staining was per-
formed according to a previous report [17]. The tissue
slides were deparaffinized, and antigen retrieval was per-
formed by immersing the slides into boiling EDTA-Tris
buffer (pH 8.2) for 4 min. After incubation with 3 %
H2O2for 15 min, slides were incubated with primary anti-
body (Rabbit polyclonal to NAV2, Abcam, ab101790,
1:1000) overnight (4 °C), followed by incubated with sec-
ondary antibody for 30 min at room temperature. DAB
(3,3-diaminobenzidine) was used to visualize positive im-
mune reaction. Nuclei were counterstained with
hematoxylin [21]. Briefly, the sections were scored using a
foutier scale according to percentage of positive cells and
staining intensity: (−) or 0, tissue specimens without
staining (0–10 %); (+) or 1, tissue specimens with weak
staining (10–25 %); (++) or 2, tissue specimens with mod-
erate staining (25–50 %) and (+++) or 3, tissue specimens
with strong staining (>50 %). (−) and (+) were defined as
low expression, and (++) and (+++) were defined as high
expression (or over-expression) [22]. The result of stain-
ing was evaluated independently by two board-certified
clinical pathologists blinded to the clinical parameters.
Any discrepancy between the two evaluators was resolved
by re-evaluation and careful discussion until agreement
was reached.
Cell culture and antibodies
Cell lines NCM460, HRT-18, Caco2, SW620, SW480,
HCT-116, LoVo, A549 and HepG2 were purchased
from the Cell Centre of Xiang Ya Medicine College of
the Central South University (Changsha, China); AGS
was obtained from the Xiang ya Central Experiment
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Laboratory, Central South University. HT-29 and RKO
Cells were a gift from Doctor Duan Q (from the Xiang
Ya Hospital of Central South University). All cells were
cultured in 1640 (Biological Industries, State of Israel).
All media were supplemented with 10 % fetal bovine
serum (Biological Industries, State of Israel). Cells were
cultured at 37 °C in humidified air with 5 % CO2. Primary
antibodies: (NAV2, SSHIL, cofilin1, p-cofilin1, Abcam;
β-actin, CST; p-SSHIL, ECM Biosciences).
RNA extraction and real-time qRT-PCR
Total RNA was extracted from cells and tissues using
TRIzol Reagent (TAKARA, JAPAN), and equal amounts
of RNA were used for real-time qRT-PCR analysis
(TAKARA, JAPAN) according to the manufacturer’s in-
structions. β-actin was used as an internal control. Below
are the specific primers used: NAV2, sense, 5’- GAGGG
ACGGGAGTTGACAGA- 3’ and antisense 5’- CAGTTG
AGCAGCCCATTGAA-3’; β-actin, sense, 5’-GCACCAC
ACCTTCTACAATGAGC - 3’ and antisense 5’- GGATA
GCACAGCCTGGATAGCAAC-3’. The 2-ΔΔCT method
was used to calculate the relative abundance of RNA for
each gene compared with β-actin expression. Each reac-
tion was performed in triplicate.
Western blotting
Tissue samples and colonic cancer cells were homog-
enized and lysed in strong RIPA buffer supplemented
with proteinase inhibitors. Equal amounts of proteins
were loaded and separated on a 6 % SDS-PAGE (sodium
dodecyl sulfate-polyacrylamide gel electrophoresis) gel.
Following electrophoresis, the proteins were transferred
to a PVDF membrane (Millipore, Billerica, MA), the
membrane was blocked in 5 % (w/v) non-fat milk and
incubated with the primary antibodies overnight, and then
secondary antibody (1:2000 dilution, CST, USA) for 1 h.
Bands were visualized and quantitated using the ECL Ad-
vance Detection System (Millipore, Billerica, MA). The
dilution of primary antibody (NAV2, 1:2000; SSHIL,
1:5000; cofilin1, 1:1000; p-cofilin1, 1:1000; p-SSHIL,
1:1000; β-actin, 1:1000).
shRNA transfection
NAV2 shRNA and the matching negative control shRNA
were purchased from the GENECHEM Company (Shang
Hai, China). The shRNAs were transfected into HCT-
116 and LoVo according to the instructions. Cells were
seeded in six-well plates at a density of 1 × 105 cells/well.
The transfection reagent and negative control shRNA
-transfected cells were used as control.
Immunofluorescence
Cells cultured in 24-well chamber slides were washed
twice with cold phosphate-buffered saline (PBS), fixed
with 4 % paraformaldehyde for 10 min, permeabilized
with 0.1 % Triton ×-100 for 5 min, blocked with 5 %
BSA, and incubated with the indicated antibodies for
F-actin at 4 °C overnight (Phalloidin-TRITC, Sigma-
Aldrich. 1:100). The cells were then stained with DAPI
(4,6-diamidino-2-phenylindole) to visualize the nuclei, and
the images were acquired with a fluorescence microscope.
In vitro motility and invasion
For the scratch wound healing assay, cells were grown to
confluence in a 6-well plate and were wounded using a
20 μl sterile pipette tip. Wound healing within the
scraped line was documented daily over 36 h, and re-
peated at least three times in duplicate. The cells’ inva-
sive ability was measured in 24-well transwell chambers
(Corning, USA). 10 % FBS was added to the bottom
chamber as a chemo-attractant. For the invasion assay,
Matrigel (1:4, BD Biosciences, USA) was added to the
transwell membrane chambers and incubated at 37 °C
for 4 h. Cells (1 × 105 cells per well) were seeded and in-
cubated for 36 h before analysis. Non-migrating cells on
the upper side of the membrane were removed, and the
cells that migrated to the lower chamber were fixed with
4 % paraformaldehyde and stained with Wright-Giemsa
to assess invasion. The number of invading cells was
determined for five randomly selected fields under a
microscope. Each experiment was performed on at least
three occasions in duplicate.
In vivo tumor metastasis
HCT-116 and LoVo cells transfected with shNAV2 and
empty vector were suspended in 1640, then injected
into the spleen of athymic nude mice (2 × 106 cells/
mouse, 5 mice per group). The spleen was resected
30 min after injection. Tumor volume was calculated
according to the following formula: length × (width)2/2.
Mice were sacrificed at day 42. All animals received hu-
mane care according to the Institutional Animal Care
and Treatment Committee of Central South University.
Statistical analysis
Statistical analysis of the differences in the expression
levels of NAV2 mRNA in paired tissues were analyzed
by the paired t-test. Correlation between NAV2 ex-
pression and clinicopathological factors was estimated
by the chi-square test. RFS and OS curves were plotted
according to the Kaplan-Meier method; A Cox regression
model was used to perform multivariate analysis, parame-
ters of significance in univariate analysis were included in
the multivariate analysis. The statistical between ≥2
groups was analyzed by Student’s t-test or one-way ana-
lysis of variance. The correlation between NAV2 expres-
sion levels and tumor budding grades were determined
Spearman’s correlation analysis. Statistical P-values < 0.05
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were considered significant. The statistical software
programs used were Prism 5 (Graph Pad Software Inc.,
La Jolla, CA, USA) and SPSS 13.0 for Windows (SPSS,
Chicago, IL).
Results
NAV2 was overexpressed in CRC tissue and associated
with the prognostic outcome of CRC patients
We investigated the relationship between NAV2 protein
or mRNA expression and clinicopathologic features in
cohort 1 or cohort 2 (Table 1; Additional file 1: Table S1).
NAV2 mRNA (Fig. 1b, paired t-test, p < 0.0001) and pro-
tein (Fig. 1e, paired t-test, p < 0.0001; Additional file 2:
Table S2) expression in tumor tissues were higher than
that in paired normal tissues. NAV2 expression was sig-
nificantly correlated with TNM stages in cohort 1 (Table 1,
chi-square test, p < 0.0001) and cohort 2 (Fig. 1d, Stu-
dent’s t-test p < 0.0001), depth of invasion, lymph
node status and distant metastasis. However, no signifi-
cant correlation was found between NAV2 expression and
other clinicopathologic variables studied such as age, gen-
der, tumor location, tumor differentiation, adjuvant ther-
apy and CEA. In addition, we found that NAV2 mRNA
(Fig. 1c, paired t-test, p = 0.0142) and protein (Fig. 1f,
paired t-test, p = 0.0043) expression in metastatic tumor
tissue were higher than in paired primary tumor tissue.
Based on these findings, we can conclude that high
expression of NAV2 was associated with more aggres-
sive biological behavior. To assess the predictive role of
NAV2 for prognosis, Kaplan-Meier curves with a log-
rank test for RFS and OS were undertaken in cohort 1
patients. There was a significant different RFS between
NAV2-positive and NAV2-negative groups after the
surgery (Fig. 2a, log-rank test, p = 0.0015). NAV2-
positive tumors had a significantly lower OS rate than
those with NAV2-negative tumors (Fig. 2a, log-rank
test, p = 0.0004).
The univariate and multivariate analysis for associ-
ation of prognostic markers of CRC with RFS and OS
are summarized in Table 2. Depth of invasion, lymph
node status, distant metastasis and NAV2 expression
were found to be prognostic factors for RFS and OS by
univariate analysis (RFS, HR = 1.616, 95 % CI: 1.094–3.205,
p = 0.014; OS, HR= 1.364, 95 % CI: 1.058–2.245, p = 0.021).
Multivariate analysis revealed that lymph node status, dis-
tant metastasis and NAV2 expression were independent
Table 1 Correlation between NAV2 protein expression and clinicopathological features of 138 CRC patients (cohort 1)
Clinicopathological features NAV2 expression
n Low (n = 47) High (n = 91) P value
Age (years) <65 67 25 42 0.433
≥65 71 22 49
Gender Male 80 30 50 0.316
Female 58 17 41
Tumor location Left colon 45 16 29 0.408
Right colon 45 12 33
Rectum 48 19 29
Tumor differentiation Well-Moderate 72 24 48 0.851
Poor 66 23 43
TNM stage I-II 37 27 10 < 0.0001
III-IV 101 20 81
Depth of invasion T1-T2 43 27 16 < 0.001
T3-T4 95 20 75
Lymph node metastasis N0 39 23 16 0.0001
N1-N2 99 24 75
Distant metastasis M0 119 45 74 0.020
M1 19 2 17
CEA <5 ng/ml 85 31 54 0.449
≥5 ng/ml 53 16 37
Adjuvant therapy YES 94 35 59 0.250
NO 44 12 32
P < 0.05 was considered statistically significant. The P values of chi-square test
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Fig. 1 (See legend on next page.)
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prognostic factors that could affect RFS and OS of CRC
patients (RFS, HR = 1.785, 95 % CI: 1.108–2.528, p = 0.010;
OS, HR= 1.564, 95 % CI: 1.108–2.376, p = 0.012).
The combination of NAV2 overexpression and high tumor
budding grade served as independent prognostic markers
for RFS and OS
When analyzing the levels of NAV2 expression in
CRC tissues by immunohisto chemistry, we found an
interesting phenomenon that high NAV2 expression
was accompanied by a high tumor budding grade.
The result of the analysis showed that high tumor
budding grade ahead of the invasive front was posi-
tively correlated with late TNM stage (Spearman’s
correlation, r = 0.3760, p < 0.0001) and high expression
level of NAV2 (Fig. 2b, Spearman’s correlation, r = 0.6208,
p < 0.0001). Multivariate analysis indicated that tumor bud-
ding grade was an independent prognostic factor that
could affect RFS and OS of CRC patients (RFS, HR= 2.021,
95 % CI: 1.156–3.126, p = 0.004; OS, HR = 2.114, 95 % CI:
1.247–4.826, p = 0.002). Meanwhile, univariate and multi-
variate analysis indicated that high NAV2 expression com-
bined with high tumor budding grade is associated with
shorter RFS and OS than other combinations with a differ-
ent status of the two factors (Table 2). In summary, NAV2
and tumor budding were independent prognostic factors
that could affected RFS and OS of CRC patients.
Inhibition of NAV2 reduced migration and invasion of
CRC cells and tumor metastasis in vitro and vivo
To investigate the expression level of NAV2 in various
cell lines including different metastatic potency CRC
cells [23–25], NAV2 protein expression levels were
tested by Western blotting (Fig. 1h). The result showed
that NAV2 was more highly expressed in strong meta-
static potency cell lines than weak metastatic potency
cell lines, and the expression level of metastatic cell line
SW460 was higher than that of primary tumor cell line
SW480. The efficacy of NAV2 knockdown was con-
firmed by real-time PCR and Western blot analyses in
HCT-116/ LoVo cell lines (Fig. 3a). In the wound heal-
ing assay, NAV2 shRNA HCT-116/LoVo cells migrated
a much shorter distance into the wound area than the
empty vector cells (Fig. 3b). Consistent with this
observation, fewer NAV2-silenced cells invaded into the
lower chamber than empty vector cells (Fig. 3c).
A liver metastatic assay was performed in nude mice
to examine the in vivo metastatic potential of NAV2
shRNA HCT-116/LoVo cells and empty vector cells
(Fig. 3d). As we can see from the results, the average
tumor volume of NAV2 shRNA HCT-116/LoVo cells
was smaller than that of the empty vector cells. The
average number of both micrometastases and macrome-
tastases in mice liver following injection of NAV2
shRNA cells was fewer than those in mice injected with
the empty vector cells as determined by H & E staining.
The extent of silencing by the shRNA vector in vivo was
verified by Western blotting. In general, these results
show that NAV2 could promote migration and invasion
of CRC cells.
Knockdown of NAV2 influenced F-actin polymerization
through the SSH1L/cofilin-1 pathway
To elucidate the potential pathway through which
NAV2 promotes cell invasion, it was necessary to val-
idate the effects of NAV2 on the downstream phos-
phorylation of SSH1L and cofilin-1 in CRC cells. Here, we
found that knockdown of NAV2 dramatically decreased
phosphorylation of SSH1L and increased phosphorylation
of cofilin-1 compared with control cell lines (Fig. 4a). Can-
cer cell migration and invasion were associated with
actin polymerization [26]. As demonstrated by the re-
sults, F-actin polymerization and stress fiber disas-
sembly were decreased in NAV2 shRNA HCT-116/
LoVo cells (Fig. 4b). The expression of p-SSH1L,
SSH1L, p-cofilin-1 and cofilin-1 in CRC tissues with
different NAV2 expression levels were detected by
Western blotting analysis (Fig. 4c). High NAV2 ex-
pression level was accompanied by increased phos-
phorylation of SSH1L and decreased phosphorylation of
cofilin-1 compared with low NAV2 expression level.
Discussion
There have been varying results concerning the roles of
NAVs in tumorigenesis and tumor progression [17, 27, 28].
Deletion of NAV3 was detected in colorectal adenomas,
cancer tissue and cell lines, the NAV3 aberrations provided
two growth advantages to a subpopulation of microsatellite
stability CRC linked to inflammation and cell proliferation
(See figure on previous page.)
Fig. 1 Overexpression of NAV2 in CRC and was associated with more aggressive tumor stage: a Immunohistochemical staining of NAV2 with
increased score ranged from stageIto IV in CRC patients from cohort 1. Magnification: ×400; scale bar, 50 μm. NAV2 mRNA level was detected by
qRT-PCR in CRC patients from cohort 2 (B-D): b, Tumor tissues (T) were higher than paired normal tissues (NT) (*P < 0.0001); c, Metastatic sites
(MS) were higher than primary tumors (PT) (**P = 0.0142); d, Stage III/IV with higher expression level than satgeI/II (***P < 0.0001). Expression levels
were normalized to those of β-actin (2-ΔΔCT). Western blotting was used to analysis NAV2 protein expression level in CRC patients from cohort 2
(e, f, g), the dates were shown in the Additional file 3: Figure S1. h NAV2 protein expression level in various metastatic potency CRC cells and other cell
lines were tested by Western blotting, NAV2 was high expression in high metastatic potency cells, experiments have been repeated three times
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pathways [29]. Previous studies have highlighted that
NAV2 was abundantly expressed in 16 of 20 colon can-
cers examined but hardly detectable in corresponding
non-cancerous mucosae using semi-quantitative RT-PCR,
NAV2 showed 3’ to 5’ helicase activity and exonuclease
activity in vitro as an oncogene. The correlation
between NAV2 expression and clinical outcomes in hu-
man CRC has not been investigated. Here, we show
that NAV2 protein and mRNA are highly expressed in
primary CRC, taking advantage of diverse detection
methods in two different cohorts. Our results are con-
sistent with previous findings [17, 18]. Contemporary,
Fig. 2 Kaplan-Meier plots with log rank test of Recurrence-free survival and Overall survival. a NAV2-positive tumors had a significantly lower rate
Recurrence-free survival (p = 0.0015) and Overall survival (p = 0.0004) than those with NAV2-negative tumors. b A significant increase tumor budding
grade ahead of the invasive front was observed with high NAV2 expression compared to low NAV2 expression. Magnification:×400; scale bar, 50 μm.
Tumor budding grade ahead of the invasive front was positive correlation with expression level of NAV2 (r = 0.621, p < 0.0001)
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NAV2 high expression was closely correlated with inva-
sion depth, and lymph node and distant metastases,
suggesting that NAV2 not only plays a key role in
tumorigenesis but also functions in CRC progression.
Multivariate analysis indicates that NAV2 overexpres-
sion is a negative prognostic factor in CRC patients in
term of the RFS and OS.
Tumor budding is defined as the presence of single
tumor cells or small groups of up to five tumor cells at
the invasive tumor front [30]. Previous studies have re-
ported that tumor budding often occurs ahead of the de-
fined invasive edge in CRC tissues [31], and the presence
of budding was significantly correlated with a higher rate
of metastasis and poor prognosis of patients [32, 33]. An
association between dynamics of cytoskeletal regulation
and tumor budding grade was demonstrated in CRC
[34]. Meanwhile, AAA+ protein family members, which
share homology with one of NAV2 functional protein
domains, have also been shown to have increased ex-
pression in CRC tumor budding [35]. According to our
findings, NAV2 was overexpressed in high tumor bud-
ding grade CRC samples, and its expression level was
positively correlated with tumor budding grade. Univariate
and multivariate analysis indicated that tumor budding
served as an independent prognostic marker for RFS and
OS in CRC patients. When evaluating NAV2 and tumor
budding in combination, patients in the low risk group
achieved the longest RFS and OS, whereas those in the
high risk group had the shortest RFS and OS. In sum,
NAV2 may promote tumor budding generation, but the
specific mechanisms require further research.
CRC cells undergo a series of pathologic events during
the metastatic process, including invading deep into the
intestinal wall, entering into the circulatory or lymphovas-
cular system, arresting at a remote site, proliferation and
induction of angiogenesis [36]. Certainly, lymph node and
distant metastasis in CRC patients is a negative prognostic
factor [37]. In our study, we found that NAV2 expression
in lymph node and liver metastases was much higher than
in matched primary CRCs, suggesting that NAV2 might
be continuously activated throughout CRC development.
In an in vitro study, we confirmed that NAV2 expression
level is correlated with metastatic potency in various cell
lines, and depletion of endogenous NAV2 in high meta-
static potency cell lines, HCT-116 and LoVo, markedly
diminished their migratory and invasive abilities. Subse-
quently, the result of liver metastatic modeling showed
that shNAV2 HCT-116 and LoVo cell lines have a
Table 2 Univariate and multivariate analysis of 138 CRC patients for RFS and OS (cohort 1)
Variables RFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
Age, years (≥65 vs. <65) 1.043 (0.756–1.132) 0.215 NA 1.038 (0.694–1.367) 0.325 NA
Gender (male vs. female) 1.162 (0.964–1.376) 0.078 NA 1.132 (0.924–1.764) 0.086 NA
Tumor location (left colon
vs. right colon vs. rectum)
1.055 (0.821–1.248) 0.133 NA 1.127 (0.885–1.526) 0.134 NA
Differentiation (poor vs.
well/ moderate)
1.204 (0.964–1.483) 0.061 NA 1.267 (0.963–1.837) 0.065 NA
TNM stage (III/IVvs.I/II) 1.436 (1.078–2.032) 0.020 1.321 (1.054–2.421) 0.025 1.512 (1.093–2.162) 0.016 1.897 (1.094–3.528) 0.013
Depth of invasion (T3/T4
vs. T1/T2)
1.267 (1.032–1.628) 0.037 1.072 (0.967–1.468) NS 1.284 (1.083–1.764) 0.028 1.173 (0.957–1.528) NS
LN metastasis (N1N2 vs. N0) 1.452 (1.082–1.936) 0.019 1.281 (1.032–1.846) 0.035 1.301 (1.075–1.964) 0.033 1.513 (1.128–3.127) 0.013
Distant metastasis (M1 vs. M0) 1.852 (1.137–2.814) 0.008 1.536 (1.108–2.162) 0.021 1.564 (1.109–2.352) 0.012 1.305 (1.106–2.642) 0.018
CEA (≥5 ng/ml vs. <5 ng/ml) 1.164 (0.925–1.637) 0.092 NA 1.173 (0.867–1.467) 0.124 NA
Adjuvant therapy
(NO vs. YES)
1.223 (0.985–1.921) 0.058 NA 1.252 (0.964–1.682) 0.072 NA
NAV2(high vs. low) 1.616 (1.094–3.205) 0.014 1.785 (1.108–2.528) 0.010 1.364 (1.058–2.245) 0.021 1.564 (1.108–2.376) 0.012
Tumor budding
(high vs. low)
1.974 (1.206–4.267) 0.005 2.021 (1.156–3.126) 0.004 1.852 (1.271–6.324) 0.006 2.114 (1.247–4.826) 0.002
aCombined NAV2 and
Tumor budding
II vs.I 2.021 (1.316–5.416) 0.002 2.157 (1.206–5.824) 0.003 1.936 (1.314–5.735) 0.004 2.052 (1.126–3.843) 0.003
III vs.I 4.828 (1.862–9.072) 0.000 5.126 (1.935–9.675) 0.000 4.352 (2.134–8.846) 0.000 4.723(1.925–9.506) 0.000
III vs.II 2.384 (1.267–7.321) 0.001 2.324 (1.221–6.326) 0.000 2.153 (1.426–6.875) 0.001 2.231(1.286–6.251) 0.0005
Abbreviations: HR hazard ratio, CI confidence interval, NA not available, NS, not significant
aI (low risk group): NAV2Low/Tumor budding Low; II (medium-risk group): NAV2High/Tumor budding Low or NAV2Low/Tumor budding
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Fig. 3 (See legend on next page.)
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decreased number of macrometastatic or micrometa-
static sites compared with the empty vector group.
These data, in concert with the present findings,
support a critical role of NAV2 in regulating invasion
and metastasis of CRC. However, so far, the mechan-
ism by which NAV2 promotes tumor cell invasion
and metastasis remains unclear, and further studies
are needed to elucidate this. Previous researchers re-
ported that NAV2 may act as a downstream target of
APC-β-catenin-TCF signaling and was related to the
Myc, APC gene [16, 38]. The NAV2 gene was found
to be frequently fused to the Wnt pathway TCF7L1
gene as a transcription factors involved in CRC re-
ported by the Cancer Genome Atlas Network [39].
(See figure on previous page.)
Fig. 3 Knockdown NAV2 inhibited migration and invasion of CRC cells in vitro and vivo. a Inhibition of NAV2 expression level in HCT-116/ LoVo
cells were testified by qRT-PCR (One-way analysis, both P< 0.0001) and Western blotting. Experiments have been repeated three times b Wound-healing
assay for NAV2 shRNA HCT-116 (Student’s t-test, *P = 0.0002) and shRNA LoVo (Student’s t-test, **P < 0.0001) compared with empty vector
cells. Photographs were taken at 36 h post wounding. Dashed lines indicated the original wound boundaries. Experiments have been repeated three
times. c Cell invasion assays, results were presented as the ratios of migrated NAV2 shRNA cells relative to those of empty vector cells
HCT-116 (Student’s t-test, *P < 0.0001) and LoVo (Student’s t-test, **P = 0.0003). Data were representative of three experiments .Original
magnification, ×100. d Representative liver metastatic tumors were shown between shRNA cells and empty vector cells; Quantification of
the liver macrometastases and micrometastases: shRNA HCT-116 and empty vector cells (Student’s t-test, ***P = 0.0003 *P = 0.0006); shRNA
LoVo and empty vector cells (Student’s t-test, ****P = 0.0023,**P = 0.0008); The average tumor volume of shRNA and the empty vector
cells: HCT-116, (Student’s t-test, *P = 0.0012); LoVo, (Student’s t-test, **P = 0.0004); The extent of silencing by shRNA in vivo was verified by
Western blotting (bottom right)
Fig. 4 Loss of NAV2 expression decreased the phosphorylation of SSH1L but increased the phosphorylation of cofilin-1. a The expressions
of p-SSH1L, SSH1L, p-cofilin-1 and cofilin-1 were detected by Western blotting analysis. Level of p-SSH1L and p-cofilin-1 protein in shRNA
and empty vector HCT-116 (Student’s t-test, *P < 0.0001, ***P = 0.0006); Level of p-SSH1L and p-cofilin-1 protein in shRNA and empty vector LoVo cells
(Student’s t-test, **P < 0.0001 ****P < 0.0001). Experiments have been repeated three times. b F-actin polymerization and stress fiber disassembly
decreased in NAV2-depleted HCT-116/LoVo cells. Experiments have been repeated three times. c The expressions level of p-SSH1L, SSH1L, p-cofilin-1
and cofilin-1 in CRC tissues with different NAV2 expression level were detected by Western blotting analysis
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Researchers have observed that Sickie, which shares struc-
tural similarities with the human neuron navigator 2
(NAV2), regulated F-actin polymerization via activating
the SSH/cofilin pathway. At the same time, NAV2 ac-
tivated the SSH1L/cofilin-1 pathway and facilitated
tumor cell migration and invasion through F-actin
polymerization. We found that knockdown of NAV2
decreases the phosphorylation of SSH1L but increases
the phosphorylation of cofilin-1 in CRC cells. Similar
results were observed in studies of CRC tissues. The
immunofluorescence results showed that loss of expres-
sion of NAV2 could regulate F-actin depolymerization
[40], which plays an essential role in tumor migration and
invasion [41]. Therefore, we concluded that NAV2 plays a
key role in promoting CRC invasion and metastasis by
regulating F-actin polymerization via the SSH1L/cofilin-1
pathway.
Conclusions
In summary, we observed that NAV2 was overex-
pressed in human CRC, and this overexpression was
associated with an unfavorable prognosis in CRC pa-
tients. Furthermore, our data demonstrate that NAV2
promotes CRC invasion and metastasis by regulating
F-actin polymerization via the SSH1L/cofilin-1 path-
way and boosting tumor budding generation in terms
of pathologic morphology. These results highlight the
importance of better understanding the role of NAV2
in CRC pathogenesis and suggest that NAV2 could be a
potential therapeutic target. However, the generalizability
of our findings is limited because this is a single-center
study. Thus, larger prospective studies are needed to fur-
ther validate our results, and specific mechanism need to
be further explored.
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